S100B水平在醉酒患者轻度创伤性脑损伤检测中的应用
该系统评价与meta分析纳入4项前瞻性队列试验,评估急性醉酒合并轻度创伤性脑损伤(MTBI)患者血清S100B水平对颅内病变的预测价值。汇总队列颅内病变患病率为10%,低于文献报告的普通MTBI人群15-30%。有与无颅内病变患者血清S100B标准均数差为0.73 μg/L(Z=18.33,P<0.001)。经敏感性分析和分层汇总受试者工作特征模型后,剩余3篇文章的汇总估计显示S100B敏感度0.96(95%CI:0.84-1.00,I2=0%)、特异度0.63(95%CI:0.58-0.68,I2=86.8%)、阴性预测值100%(95%CI:95.14-100,I2=0%)、阴性似然比0.06(95%CI:0.01-0.31)。作者结论认为S100B可能有助于排除颅内病变,但尚需更多研究及与其他血清脑损伤标志物的比较。
要点
- 在急性醉酒合并MTBI患者中,汇总队列颅内病变患病率为10%,低于文献报告的普通MTBI人群15-30%。
- 有与无颅内病变患者血清S100B标准均数差为0.73 μg/L(Z=18.33,P<0.001)。
- 汇总3项研究显示S100B排除颅内病变的敏感度0.96(95%CI:0.84-1.00,I2=0%)、特异度0.63(95%CI:0.58-0.68,I2=86.8%)。
- S100B的阴性预测值为100%(95%CI:95.14-100,I2=0%),阴性似然比0.06(95%CI:0.01-0.31)。
- 作者认为S100B可能有助于排除醉酒MTBI患者的颅内病变,但尚需更多研究及与其他血清标志物比较后才能成为公认标准。
适用人群与场景
- 急性醉酒合并轻度创伤性脑损伤(MTBI)患者,来自4项前瞻性队列试验。
研究设计与关键结果
- 研究类型为系统评价与meta分析,纳入4项前瞻性队列试验,评估急性醉酒MTBI患者血清S100B水平。
- 汇总队列颅内病变患病率为10%,低于文献报告的普通MTBI人群15-30%。
- 有与无颅内病变患者血清S100B标准均数差为0.73 μg/L(Z=18.33,P<0.001)。
- 经敏感性分析和分层汇总受试者工作特征模型后,剩余3篇文章汇总估计:敏感度0.96(95%CI:0.84-1.00,I2=0%)、特异度0.63(95%CI:0.58-0.68,I2=86.8%)。
- 阴性预测值100%(95%CI:95.14-100,I2=0%),阴性似然比0.06(95%CI:0.01-0.31)。
证据类型、等级与局限
- 证据类型:系统评价与meta分析,纳入4项前瞻性队列试验。
- 作者结论:S100B可能有助于排除醉酒MTBI患者的颅内病变,但尚需更多研究及与其他血清脑损伤标志物比较后才能成为公认标准。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血清S100B水平可能有助于排除急性醉酒合并MTBI患者的颅内病变。
- 作者认为在S100B成为公认标准前,尚需更多研究及与其他血清脑损伤标志物的比较。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: S100B is a serum protein known to elevate in patients with brain injury, but it is unknown whether it can predict intracranial pathology in intoxicated patients following mild traumatic brain injury (MTBI). We performed a systematic review and meta-analysis of the English language literature to address this question.
MAIN OUTCOMES AND RESULTS: Four prospective cohort trials of serum S100B levels on acutely intoxicated patients with MTBI were included in this meta-analysis. Prevalence of intracranial pathology in the pooled cohort of the intoxicated MTBI patients was 10%, lower than the 15-30% reported in the literature for the general MTBI population. Standard mean difference of serum S100B levels between patients with and without intracranial pathology on CT was 0.73 μg/L (Z = 18.33, P < 0.001). Following sensitivity analysis and hierarchical summary receiver-operating characteristic models, three remaining articles were used for pooled estimates that found that S100B had a sensitivity of 0.96 (95% CI: 0.84-1.00, I2 = 0%) and specificity of 0.63 (95% CI: 0.58-0.68, I2 = 86.8%) with a high negative predictive value (100%, 95% CI: 95.14-100, I2 = 0%) and a negative LR of 0.06 (95% CI: 0.01-0.31).
CONCLUSIONS: Serum S100B levels may have utility in ruling out intracranial pathology in intoxicated patients, however more study and comparison with other serum biomarkers of brain injury are necessary before this becomes the accepted standard of care.
参考来源
- Rahimian S, Potteiger S, Loynd R, et al. The utility of S100B level in detecting mild traumatic brain injury in intoxicated patients. Am J Emerg Med. 2019. PMID: 31884023. doi:10.1016/j.ajem.2019.12.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。